GENZYME PLANS OCTOBER LAUNCH OF SEPRAFILM BIORESORBABLE ANTI-ADHESION MEMBRANE; FDA APPROVAL COVERS BROAD USE IN ABDOMINAL, PELVIC PROCEDURES
This article was originally published in The Gray Sheet
Executive Summary
Genzyme's October launch of Seprafilm will be the first test for a sales force that recently tripled in size through an acquisition. The bioresorbable anti-adhesion membrane for post surgical applications was approved by FDA on Aug. 13.